4/4/2024 | SP | New Issue: CIBC sells $2.75 million contingent coupon autocallable barrier notes on three stocks
|
9/14/2023 | SP | New Issue: JPMorgan prices $350,000 7.2% autocallable yield notes linked to Gilead
|
9/7/2023 | IG | New Issue: Gilead Sciences sells $2 billion of senior notes due 2033, 2053
|
9/7/2023 | BKIG | Moody's assigns A3 to Gilead notes
|
9/7/2023 | IG | Gilead Sciences readies offering of three fixed-rate senior notes
|
8/31/2023 | SP | New Issue: UBS sells $2.33 million capped trigger gears on basket of 40 stocks
|
8/15/2023 | SP | New Issue: JPMorgan prices $1.29 million trigger autocallable contingent yield notes on Gilead Sciences
|
5/18/2023 | BKIG | S&P revises Gilead outlook to positive
|
3/9/2023 | SP | New Issue: Citigroup prices $2.42 million contingent income autocallables linked to Gilead
|
3/1/2023 | SP | New Issue: UBS prices $545,000 trigger autocallable contingent yield notes on Gilead Sciences
|
2/15/2023 | SP | New Issue: UBS prices $1.93 million contingent income autocallable securities on Gilead
|
2/8/2023 | SP | New Issue: JPMorgan prices $1.4 million contingent income autocallables on Gilead
|
11/2/2022 | SP | New Issue: UBS prices $945,000 trigger autocallable contingent yield notes on Gilead Sciences
|
11/1/2022 | SP | New Issue: JPMorgan prices $241,000 autocallable contingent interest notes on pharma stocks
|
10/28/2022 | SP | New Issue: Citigroup prices $305,000 12% autocallable contingent coupon equity notes on Gilead
|
10/25/2022 | SP | New Issue: GS Finance sells $494,000 of 8% autocallable fixed-coupon notes on Gilead
|
10/1/2022 | SP | New Issue: Credit Suisse sells $1.07 million contingent coupon autocallable yield notes on two stocks
|
8/29/2022 | SP | New Issue: JPMorgan prices $397,000 8.25% autocallable yield notes linked to Gilead
|
8/24/2022 | SP | New Issue: Citigroup prices $3.38 million contingent income autocalls on Gilead
|
8/4/2022 | BKIG | Moody's alters Gilead outlook to stable
|
6/8/2022 | SP | New Issue: JPMorgan prices $750,000 autocallable contingent interest notes on pharma stocks
|
5/16/2022 | SP | New Issue: HSBC sells $526,000 callable contingent income barrier notes on four stocks
|
4/26/2022 | SP | New Issue: Credit Suisse sells $1.75 million accelerated barrier notes on basket
|
4/18/2022 | IG | S&P changes Gilead Sciences view to stable
|
2/17/2022 | SP | New Issue: Citigroup prices $4.17 million contingent income autocalls on Gilead
|
2/11/2022 | SP | New Issue: UBS prices $1 million trigger autocallable contingent yield notes on three stocks
|
1/14/2022 | SP | New Issue: Citi prices $1.5 million autocallable contingent coupon equity notes on two stocks
|
1/3/2022 | SP | New Issue: JPMorgan prices $7.67 million contingent income autocallables on Gilead Sciences
|
12/17/2021 | SP | New Issue: Credit Suisse sells $3.83 million contingent coupon autocallable yield notes on stocks
|
12/7/2021 | SP | New Issue: HSBC sells $710,000 contingent income barrier autocalls on Gilead, Amgen, Merck
|
11/10/2021 | SP | New Issue: JPMorgan sells $1.95 million trigger autocallable contingent yield notes on Gilead
|
9/24/2021 | SP | New Issue: JPMorgan prices $8.28 million contingent income autocallables on Gilead Sciences
|
9/14/2021 | SP | New Issue: JPMorgan sells $2.29 million autocallable contingent interest notes on three stocks
|
6/15/2021 | SP | New Issue: JPMorgan prices $11.7 million contingent income autocallables on Gilead
|
6/5/2021 | SP | New Issue: CIBC sells $2.5 million of 6.504% fixed-interest barrier notes on three stocks
|
4/14/2021 | SP | New Issue: UBS prices $201,000 trigger phoenix autocallables linked to Gilead Sciences
|
4/14/2021 | SP | New Issue: UBS prices $247,000 trigger phoenix autocallables linked to Gilead Sciences
|
3/23/2021 | SP | New Issue: GS Finance sells $8.31 million contingent income autocalls on Gilead Sciences
|
1/25/2021 | SP | New Issue: RBC sells $10.06 million 7.25% airbag autocallable yield notes on Gilead
|
1/18/2021 | SP | New Issue: JPMorgan sells $3.63 million autocallable contingent interest notes on Gilead Sciences
|
12/15/2020 | SP | New Issue: UBS prices $161,000 trigger phoenix autocallables linked to Gilead
|
12/8/2020 | SP | New Issue: UBS prices $224,000 trigger phoenix autocallables linked to Gilead Sciences
|
10/28/2020 | SP | New Issue: UBS prices $10 million buffered income autocallables tied to Gilead
|
10/27/2020 | BKIG | S&P cuts Gilead
|
10/14/2020 | SPSW | Agents sell $237 million to start Q3; single-index pricing improving; leverage still declining
|
10/7/2020 | SP | New Issue: UBS prices $500,000 trigger phoenix autocallables linked to Gilead
|
9/25/2020 | EMHYPFPV | Market Commentary: BlackRock, Consumers Energy, EIB price; light supply forecast; Gilead, T-Mobile mixed
|
9/25/2020 | IG | Market Commentary: BlackRock, Consumers Energy, EIB price; light supply forecast; Gilead, T-Mobile mixed
|
9/25/2020 | IG | Market Commentary: Morning Commentary: BlackRock plans high-grade bond tap; Gilead, B.A.T., T-Mobile mixed
|
9/24/2020 | IG | Market Commentary: High-grade supply thins; Avolon, Ontario Teachers price; bonds mixed; inflows decline
|
9/24/2020 | IG | Market Commentary: Morning Commentary: High-grade supply thins; Ontario Teachers on deck; Gilead mixed
|
9/24/2020 | IG | New Issue: Gilead Sciences details $7.25 billion of senior notes in seven parts
|
9/23/2020 | EMHYPFPV | Market Commentary: High-grade issuers flood primary; Gilead, Equinix, AerCap price; Ontario Teachers in pipeline
|
9/23/2020 | IG | Market Commentary: High-grade issuers flood primary; Gilead, Equinix, AerCap price; Ontario Teachers in pipeline
|
9/23/2020 | IG | New Issue: Gilead Sciences prices $6.75 billion of senior notes in six tranches
|
9/23/2020 | BKIG | Moody’s assigns A3 to Gilead notes
|
9/23/2020 | IG | Market Commentary: Morning Commentary: High-grade issuers deluge primary; Gilead, Equinix, AerCap on deck
|
9/23/2020 | IG | Gilead Sciences offers floating-, fixed-rate notes in six parts
|
9/22/2020 | BKIG | S&P rates Gilead notes, loans A
|
9/14/2020 | BKIG | S&P puts Gilead on watch
|
9/14/2020 | BKIG | Gilead eyes $6 billion new debt to finance acquisition of Immunomedics
|
9/9/2020 | SP | New Issue: JPMorgan sells $815,000 contingent interest autocalls on Gilead Sciences
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
8/28/2020 | SP | JPMorgan to price contingent interest autocalls tied to Gilead Sciences
|
8/17/2020 | SP | New Issue: Citigroup prices $1.01 million contingent coupon autocallables on three stocks
|
7/16/2020 | SP | New Issue: UBS prices $245,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/16/2020 | SP | New Issue: UBS prices $290,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/18/2020 | SP | New Issue: Goldman prices $7.88 million leveraged basket-linked notes on 62 stocks
|
6/4/2020 | SP | New Issue: RBC sells $485,000 contingent coupon barrier autocalls on two stocks
|
5/27/2020 | SP | New Issue: GS Finance sells $2.99 million contingent income autocalls on Gilead Sciences
|
5/26/2020 | SP | New Issue: Goldman prices $2.12 million leveraged buffered basket-linked notes on 26 stocks
|
5/21/2020 | SP | New Issue: RBC prices $491,000 contingent coupon barrier autocalls on Gilead Sciences
|
5/15/2020 | SP | GS Finance plans to price contingent income autocalls on Gilead
|
5/14/2020 | SP | New Issue: Barclays sells $3.22 million phoenix autocallable notes on three stocks
|
5/5/2020 | SP | New Issue: Barclays sells $4.56 million contingent income autocalls on Gilead
|
4/28/2020 | SP | New Issue: UBS prices $1 million trigger autocallable contingent yield notes on Gilead
|
4/28/2020 | SP | New Issue: Goldman prices $910,000 leveraged basket-linked notes on 26 stocks
|
4/28/2020 | SP | New Issue: RBC prices $2.78 million contingent coupon barrier autocalls on Gilead Sciences
|
4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
4/23/2020 | SP | New Issue: Goldman prices $9.16 million leveraged basket-linked notes on 26 stocks
|
4/20/2020 | SP | UBS to price trigger autocallable contingent yield notes on Gilead Sciences
|
4/15/2020 | SP | New Issue: UBS prices $245,000 trigger phoenix autocallables linked to Gilead
|
4/15/2020 | SP | New Issue: UBS prices $260,000 trigger phoenix autocallables linked to Gilead
|
3/12/2020 | SP | New Issue: JPMorgan prices $698,000 contingent interest autocalls on Gilead Sciences
|
3/6/2020 | SP | New Issue: RBC prices $739,000 contingent coupon barrier autocalls on three stocks
|
3/5/2020 | SP | New Issue: RBC sells $1.94 million contingent coupon barrier autocalls on Gilead, L3Harris
|
2/24/2020 | SP | New Issue: CIBC prices $750,000 capped leveraged notes on basket of 50 stocks
|
2/10/2020 | SP | New Issue: Citi sells $1.18 million callable contingent coupon notes on two ETFs, Gilead Sciences
|
1/23/2020 | SP | New Issue: HSBC prices $14.21 million contingent income autocallables on Gilead Sciences
|
1/16/2020 | SP | New Issue: Scotia sells $6.05 million capped enhanced participation notes on basket of 49 stocks
|
1/10/2020 | SP | New Issue: UBS prices $245,000 trigger phoenix autocallables linked to Gilead
|
1/7/2020 | SP | New Issue: UBS prices $185,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/7/2020 | SP | New Issue: JPMorgan sells $1.17 million contingent interest autocalls on pharma stocks
|
12/24/2019 | SP | New Issue: Citigroup prices $4.77 million contingent coupon autocallables on Eli Lilly, Gilead
|
12/20/2019 | SP | New Issue: Citigroup prices $2.07 million contingent coupon autocallables on two stocks
|
12/13/2019 | SP | New Issue: UBS prices $640,000 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
12/13/2019 | SP | New Issue: UBS prices $1.4 million contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
12/13/2019 | SP | New Issue: UBS prices $260,000 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
11/18/2019 | SP | New Issue: RBC prices $719,000 contingent coupon barrier notes linked to Biogen, Gilead Sciences
|
11/14/2019 | SP | RBC intends to price contingent coupon barrier autocalls on two stocks
|
10/15/2019 | SP | New Issue: UBS prices $200,000 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
8/20/2019 | SP | New Issue: RBC sells $135,000 contingent coupon barrier autocalls on three stocks
|
8/7/2019 | SP | New Issue: JPMorgan prices $1.8 million contingent interest autocalls linked to pharma stocks
|
7/30/2019 | SP | New Issue: JPMorgan prices $1.84 million contingent interest autocallables linked to pharma stocks
|
7/25/2019 | SP | New Issue: JPMorgan prices $647,000 contingent interest autocallables linked to Gilead Sciences
|
7/15/2019 | SP | JPMorgan to price contingent interest autocallables on three stocks
|
6/26/2019 | SP | New Issue: CIBC sells $133,000 notes tied to 14 Raymond James Healthcare top picks
|
6/26/2019 | SP | New Issue: CIBC sells $253,000 notes tied to 14 Raymond James Healthcare top picks
|
6/7/2019 | SP | CIBC plans Raymond James Healthcare Top Selections notes on 14 stocks
|
6/7/2019 | SP | CIBC eyes Raymond James Healthcare Top Selections notes on 14 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $370,000 Raymond James Healthcare Top Selections notes on 15 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $1.64 million Raymond James Healthcare Top Selections notes on 15 stocks
|
5/14/2019 | SP | New Issue: UBS prices $642,000 trigger autocallables linked to Gilead Sciences
|
5/10/2019 | SP | New Issue: RBC sells $12.3 million 7% airbag autocallable yield notes on Gilead
|
5/9/2019 | SP | UBS plans to price trigger autocallables linked to Gilead Sciences
|
5/2/2019 | SP | RBC plans to price 7% airbag autocallable yield notes on Gilead Sciences
|
4/11/2019 | SP | New Issue: CIBC sells $3.72 million notes on Raymond James stock selections
|
4/11/2019 | SP | New Issue: CIBC sells $701,000 notes on Raymond James equity securities selections
|
3/20/2019 | SP | New Issue: BofA sells $1.23 million contingent income autocallables on two stocks
|
3/14/2019 | SP | BofA to price contingent income autocallables on Gilead, Marathon
|
3/6/2019 | SP | New Issue: Citigroup sells $500,000 autocallable equity-linked notes on four stocks
|
2/19/2019 | SP | New Issue: RBC prices $1.61 million 11% callable notes on three pharma stocks
|
2/14/2019 | SP | Citigroup plans autocallable equity-linked notes tied to four stocks
|
2/12/2019 | SP | RBC plans to price 11% callable notes linked to three pharma stocks
|
1/9/2019 | SP | New Issue: Credit Suisse sells $500,000 contingent coupon autocallable yield notes on stocks
|
11/27/2018 | SP | New Issue: HSBC sells $2.67 million 9.3% airbag autocallable yield notes on Gilead Sciences
|
11/15/2018 | SP | HSBC eyes 8.1%-9.1% airbag autocallable yield notes on Gilead Sciences
|
10/31/2018 | SP | New Issue: BMO sells $150,000 notes on Raymond James quality yield stock basket
|
10/31/2018 | SP | New Issue: BMO sells $315,000 notes on Raymond James quality yield stock basket
|
10/31/2018 | SP | New Issue: BMO sells $292,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: BMO sells $390,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: CIBC sells $120,000 notes on Raymond James top pick healthcare stocks
|
10/31/2018 | SP | New Issue: CIBC sells $400,000 notes on Raymond James top pick healthcare stocks
|
10/26/2018 | SP | New Issue: JPMorgan prices $1.33 million 9.5% contingent interest autocalls on two stocks
|
10/23/2018 | SP | New Issue: JPMorgan prices $500,000 of 10% contingent interest autocalls on stocks
|
10/19/2018 | SP | New Issue: Credit Suisse sells $1.24 million contingent coupon autocallable reverse convertibles on Gilead
|
10/18/2018 | SP | CIBC to price notes on 11 Raymond James top pick healthcare stocks
|
10/18/2018 | SP | CIBC plans notes on 11 Raymond James top pick healthcare stocks
|
10/11/2018 | SP | BMO plans notes due 2020 tied to Raymond James biotech top picks
|
10/11/2018 | SP | BMO to price notes due 2020 tied to Raymond James biotech top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.23 million notes on eight Raymond James Biotechnology Sector top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.02 million notes on eight Raymond James Biotechnology Sector top picks
|
9/26/2018 | SP | New Issue: Barclays prices $714,000 of 15% phoenix autocalls tied to three stocks
|
9/20/2018 | SP | New Issue: Credit Suisse sells $729,000 6.7% autocallable reverse convertibles on Gilead
|
8/27/2018 | SP | New Issue: Morgan Stanley sells $1.02 million 11.24% worst-of autocall RevCons on three stocks
|
8/16/2018 | SP | New Issue: RBC prices $542,000 8.85% contingent coupon autocalls on three stocks
|
8/8/2018 | SP | New Issue: RBC sells $1.4 million contingent coupon barrier autocalls on three stocks
|
8/8/2018 | SP | RBC plans 8.85%-9.85% contingent coupon autocalls tied to three stocks
|
7/31/2018 | SP | New Issue: Credit Suisse sells $1.45 million contingent coupon autocallable reverse convertibles on three stocks
|
7/23/2018 | SP | RBC plans 8.4%-9.6% contingent coupon autocalls tied to three stocks
|
4/19/2018 | SP | New Issue: Barclays sells $1.23 million 10.25% contingent income autocalls tied to Gilead Sciences
|
3/16/2018 | SP | New Issue: GS Finance prices $6.85 million contingent income autocallables on Gilead
|
3/8/2018 | SP | New Issue: Goldman prices $7.79 million 10.25% contingent income autocalls on Gilead
|
3/5/2018 | SP | New Issue: BMO sells $28,000 bullish enhanced notes on Ameriprise IRG Quality Factor stocks
|
3/5/2018 | SP | New Issue: BMO sells $198,000 bullish enhanced notes on Ameriprise IRG Quality Factor stocks
|
3/5/2018 | SP | New Issue: BMO sells $88,000 bullish enhanced notes on Ameriprise IRG Quality Factor stocks
|
3/5/2018 | SP | New Issue: BMO sells $63,000 bullish enhanced notes on Ameriprise IRG Quality Factor stocks
|
3/1/2018 | SP | New Issue: Barclays sells $3.63 million 9.2% contingent income autocalls tied to Gilead
|
2/22/2018 | SP | BMO eyes bullish enhanced notes on Ameriprise Quality Factor stocks
|
2/22/2018 | SP | BMO plans bullish enhanced notes on Ameriprise Quality Factor stocks
|
2/22/2018 | SP | BMO to sell bullish enhanced notes on Ameriprise Quality Factor stocks
|
2/22/2018 | SP | BMO to price bullish enhanced notes on Ameriprise Quality Factor stocks
|
2/13/2018 | SP | New Issue: UBS prices $882,500 trigger phoenix autocallables linked to Gilead Sciences
|
2/9/2018 | SP | New Issue: Citigroup sells $572,000 autocallable equity-linked notes tied to pharma stocks
|
2/9/2018 | SP | New Issue: Citi sells $1.83 million 12% contingent coupon autocalls tied to four stocks
|
2/7/2018 | SP | New Issue: Citi sells $344,000 9% contingent coupon autocalls tied to three stocks
|
2/1/2018 | SP | New Issue: Credit Suisse sells $2.22 million contingent coupon autocallable yield notes on stocks
|
1/22/2018 | SP | Credit Suisse plans 10% contingent coupon autocallables on stocks
|
1/19/2018 | SP | New Issue: UBS prices $140,000 trigger phoenix autocallables linked to Gilead
|
1/19/2018 | SP | New Issue: JPMorgan sells $784,000 contingent interest autocallables on Gilead
|
1/12/2018 | SP | Citi plans 9% contingent coupon autocallables tied to three stocks
|
1/12/2018 | SP | Citi plans 12% contingent coupon autocallables tied to four stocks
|
12/26/2017 | SP | New Issue: Wells Fargo prices $2 million 9% contingent market-linked autocalls tied to stocks
|
12/20/2017 | SP | New Issue: Barclays sells $813,000 two-year phoenix autocallables tied to four stocks
|
12/14/2017 | SP | New Issue: RBC prices $1.83 million 11.68% contingent coupon autocalls linked to stocks
|
12/6/2017 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Gilead
|
12/5/2017 | SP | New Issue: RBC prices $500,000 contingent coupon barrier autocallables on Gilead
|
11/29/2017 | SP | New Issue: Morgan Stanley sells $6.79 million contingent income autocallables tied to Gilead
|
11/15/2017 | SP | New Issue: JPMorgan sells $1.99 million contingent income autocallables tied to Gilead
|
11/15/2017 | SPSW | Sales are slow in early part of the month with $231 million; single-stocks volume is up
|
11/13/2017 | SP | Morgan Stanley plans contingent income autocallables linked to Gilead
|
11/13/2017 | SP | New Issue: UBS prices $647,500 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/1/2017 | SP | New Issue: HSBC prices $10.94 million contingent income autocallables tied to Gilead
|
10/26/2017 | SP | New Issue: Morgan Stanley sells $3.42 million 5.52% contingent income autocalls on pharma stocks
|
10/24/2017 | SP | HSBC plans 8.6% three-year contingent income autocalls tied to Gilead
|
10/11/2017 | SP | New Issue: Morgan Stanley prices $2.96 million contingent income autocallables on three stocks
|
10/2/2017 | SP | New Issue: Credit Suisse prices $2.79 million contingent coupon autocallables linked to Gilead
|
9/27/2017 | SP | New Issue: Credit Suisse prices $500,000 10% autocallable reverse convertibles linked to pharma stocks
|
9/21/2017 | SP | Credit Suisse plans contingent coupon reverse convertibles on Gilead
|
9/14/2017 | EMHYPFPV | Market Commentary: High-grade supply robust; Gilead Sciences, BP, Scotiabank, Quebec, Kommuninvest price
|
9/14/2017 | IG | Market Commentary: High-grade supply robust; Gilead Sciences, BP, Scotiabank, Quebec, Kommuninvest price
|
9/14/2017 | IG | New Issue: Gilead Sciences prices $3 billion of senior notes in four tranches
|
9/14/2017 | BKIG | S&P: Gilead Sciences notes A
|
9/14/2017 | IG | Market Commentary: Morning Commentary: Scotiabank, Gilead Sciences market notes; Quebec, Kommuninvest to price
|
9/14/2017 | IG | Gilead to sell notes in four parts to fund Kite Pharma acquisition
|
9/13/2017 | BK | Gilead enters term loans totaling $6 billion for Kite acquisition
|
8/31/2017 | SP | New Issue: Barclays prices $2.16 million phoenix autocallables tied to three stocks
|
8/28/2017 | IG | Moody's affirms Gilead at A3
|
8/28/2017 | BKBWIG | Gilead to take on bank debt, issue senior notes for Kite acquisition
|
8/8/2017 | SP | New Issue: JPMorgan prices $4.27 million contingent income autocallables linked to Gilead
|
8/8/2017 | SP | New Issue: JPMorgan prices $2.46 million contingent income autocallables linked to Gilead
|
7/31/2017 | SP | JPMorgan plans contingent income autocallables tied to Gilead Sciences
|
6/22/2017 | SP | New Issue: Credit Suisse sells $3.44 million contingent coupon autocallable reverse convertibles on Gilead
|
6/6/2017 | SP | New Issue: Barclays sells $2.55 million phoenix autocallable notes on three stocks
|
5/11/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
5/11/2017 | SP | Barclays plans phoenix autocallables due 2020 linked to three stocks
|
4/18/2017 | SP | New Issue: Credit Suisse sells $679,000 autocallable yield notes on pharma stocks
|
4/3/2017 | SP | New Issue: Credit Suisse sells $2.68 million trigger autocallable notes on Gilead
|
3/23/2017 | SP | Credit Suisse plans trigger autocallable notes linked to Gilead
|
3/13/2017 | SP | New Issue: UBS prices $795,000 trigger phoenix autocallables linked to Gilead Sciences
|
3/3/2017 | SP | New Issue: UBS prices $1.49 million phoenix autocallable memory interest notes on Gilead Sciences
|
3/1/2017 | SP | New Issue: UBS prices $105,000 trigger phoenix autocallables linked to Gilead
|
2/24/2017 | SP | Market Commentary: UBS’ phoenix autocallables tied to Gilead Sciences to show various risk-return outcomes
|
2/22/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Gilead Sciences
|
2/22/2017 | SP | UBS plans phoenix autocallable memory interest notes on Gilead Sciences
|
2/14/2017 | SP | New Issue: UBS prices $109,000 trigger phoenix autocallables linked to Gilead
|
2/13/2017 | SP | New Issue: UBS prices $633,500 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
2/6/2017 | SP | New Issue: HSBC sells $10.7 million contingent income autocallables tied to Gilead
|
1/27/2017 | SP | New Issue: JPMorgan prices $1 million contingent interest autocallables tied to pharma stocks
|
1/23/2017 | SP | HSBC plans to price contingent income autocallables tied to Gilead Sciences
|
1/19/2017 | SP | New Issue: UBS prices $110,000 trigger phoenix autocallables linked to Gilead
|
1/19/2017 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Gilead
|
1/12/2017 | SP | JPMorgan plans contingent interest autocallables tied to three stocks
|
12/12/2016 | SP | New Issue: Morgan Stanley sells $3.85 million worst-of autocallable RevCons on three stocks
|
11/18/2016 | SP | New Issue: UBS prices $303,000 trigger phoenix autocallables linked to Gilead Sciences
|
11/18/2016 | SP | New Issue: UBS prices $167,000 trigger phoenix autocallables linked to Gilead Sciences
|
11/16/2016 | SP | New Issue: JPMorgan sells $228,000 8% autocallable yield notes linked to Gilead
|
11/15/2016 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/8/2016 | SP | JPMorgan plans 8% one-year autocallable yield notes linked to Gilead
|
10/28/2016 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Gilead
|
10/24/2016 | SP | New Issue: UBS prices $150,000 return optimization securities on Gilead Sciences
|
10/20/2016 | SP | New Issue: UBS prices $185,000 airbag yield optimization notes on Gilead
|
10/18/2016 | SP | New Issue: GS prices $6.78 million contingent income autocallables linked to Gilead Sciences
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs to price variable coupon CDs due 2023 tied to 10 stocks
|
10/7/2016 | SP | GS Finance plans contingent income autocallables linked to Gilead
|
10/3/2016 | SP | New Issue: JPMorgan sells $560,000 of contingent interest autocallables on Gilead
|
9/23/2016 | SP | JPMorgan plans contingent interest autocallable notes tied to Gilead
|
9/21/2016 | SP | New Issue: Credit Suisse prices $3.32 million contingent coupon autocallables tied to Gilead
|
9/20/2016 | SP | New Issue: HSBC prices $715,000 phoenix quarterly review notes linked to Gilead
|
9/19/2016 | EMHYPFPV | Market Commentary: Shire prices $12.1 billion; Hess, American Airlines, S&P tap market; credit spreads firm
|
9/19/2016 | IG | Market Commentary: Shire prices $12.1 billion; Hess, American Airlines, S&P tap market; credit spreads firm
|
9/19/2016 | IG | Market Commentary: Morning Commentary: Supply light; Gilead improves; Ingredion tightens; credit spreads firm
|
9/16/2016 | EMHYPFPV | Market Commentary: Active deal week forecast; Gilead Sciences, Cisco firm; 3M improves; credit spreads soften
|
9/16/2016 | IG | Market Commentary: Active deal week forecast; Gilead Sciences, Cisco firm; 3M improves; credit spreads soften
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/16/2016 | IG | New Issue: Gilead Sciences details $5 billion five-tranche offer of senior notes
|
9/15/2016 | EMHYPFPV | Market Commentary: Gilead sells $5 billion; Freddie Mac, Pitney Bowes, CCL price; credit spreads tighten
|
9/15/2016 | IG | Market Commentary: Gilead sells $5 billion; Freddie Mac, Pitney Bowes, CCL price; credit spreads tighten
|
9/15/2016 | IG | New Issue: Gilead Sciences prices $5 billion senior notes in five tranches
|
9/15/2016 | CVIG | S&P: Gilead Sciences notes A
|
9/15/2016 | CVIG | Moody’s gives A3 to Gilead notes
|
9/15/2016 | IG | Market Commentary: Morning Commentary: Primary supply heavy; Thermo Fisher, BP mostly flat; credit spreads firm
|
9/15/2016 | IG | Gilead Sciences to conduct offering of senior notes in five tranches
|
9/13/2016 | SP | HSBC plans phoenix quarterly review notes linked to Gilead Sciences
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 tied to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
9/7/2016 | SP | Credit Suisse plans contingent coupon autocallable yield notes on Gilead
|
9/6/2016 | SP | New Issue: UBS prices $120,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/2/2016 | SP | New Issue: Credit Suisse sells $2.82 million of 8.25% autocallable reverse convertibles on Gilead
|
9/1/2016 | SP | New Issue: JPMorgan prices $1.95 million contingent interest autocallables linked to Gilead
|
8/26/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Gilead
|
8/23/2016 | SP | New Issue: RBC prices $760,000 contingent coupon barrier autocallables on Gilead
|
8/22/2016 | SP | JPMorgan plans three-month contingent interest autocallables on Gilead
|
8/16/2016 | SP | Credit Suisse plans autocallable reverse convertibles linked to Gilead
|
8/15/2016 | SP | New Issue: TD Bank prices $4.4 million 6.4% autocallable barrier notes linked to Gilead Sciences
|
8/9/2016 | SP | New Issue: Credit Suisse prices $11.39 million trigger autocallables linked to Gilead Sciences
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
8/8/2016 | SP | New Issue: JPMorgan prices $600,000 callable contingent interest notes linked to Gilead Sciences
|
8/4/2016 | SP | Credit Suisse to price trigger autocallables linked to Gilead Sciences
|
7/29/2016 | SP | New Issue: UBS prices $128,000 trigger phoenix autocallables linked to Gilead
|
7/29/2016 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Gilead
|
7/27/2016 | SP | New Issue: UBS prices $436,000 trigger autocallables linked to Gilead Sciences
|
7/26/2016 | SP | New Issue: UBS prices $175,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/26/2016 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/26/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/26/2016 | SP | New Issue: UBS prices $99,853 6.31% trigger yield optimization notes linked to Gilead Sciences
|
7/20/2016 | SP | New Issue: UBS prices $110,000 trigger phoenix autocallables linked to Gilead
|
7/19/2016 | SP | New Issue: Barclays prices $1.11 million phoenix autocallables linked to Gilead
|
7/15/2016 | SP | New Issue: JPMorgan prices $540,000 7.5% autocallable yield notes linked to Gilead
|
7/12/2016 | SP | Barclays to price phoenix autocallables linked to Gilead Sciences
|
7/11/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
7/1/2016 | SP | New Issue: Morgan Stanley prices $2.16 million contingent income autocallables on IBM, Gilead
|
6/21/2016 | SP | JPMorgan to price 7.5%-9.5% autocallable yield notes linked to Gilead
|
6/14/2016 | SP | New Issue: JPMorgan prices $1.63 million 7.5% callable reverse exchangeables linked to Gilead Sciences
|
6/13/2016 | SP | New Issue: Deutsche Bank prices $1.14 million autocallable securities on Gilead
|
6/13/2016 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2021 on 10 stocks
|
6/13/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2023 on 10 stocks
|
6/13/2016 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2026 on 10 stocks
|
6/13/2016 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2023 on 10 stocks
|
6/3/2016 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Gilead
|
6/1/2016 | SP | JPMorgan plans 7.5%-9.5% callable reverse exchangeables tied to Gilead
|
5/23/2016 | SP | New Issue: Credit Suisse prices $1.82 million contingent coupon autocallables on pharma stocks
|
5/18/2016 | CVIG | Moody’s cuts Gilead Sciences to stable
|
5/18/2016 | SP | Credit Suisse plans contingent coupon autocallable yield notes linked to three stocks
|
5/17/2016 | SP | New Issue: JPMorgan prices $676,000 contingent interest autocallables linked to pharma stocks
|
5/11/2016 | SP | New Issue: JPMorgan prices $1.31 million autocallable contingent interest notes tied to Gilead
|
5/10/2016 | SP | New Issue: JPMorgan prices $8.12 million trigger autocallables linked to Gilead Sciences
|
5/9/2016 | SP | Goldman Sachs plans variable-coupon CDs due 2023 tied to stock basket
|
5/9/2016 | SP | Goldman Sachs Bank to price variable-coupon CDs due 2023 on 10 stocks
|
5/9/2016 | SP | Goldman Sachs plans variable-coupon CDs due 2023 linked to 10 stocks
|
5/9/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2020 on 10 stocks
|
5/9/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2026 on 10 stocks
|
5/9/2016 | SP | Goldman Sachs Bank plans variable-coupon CDs due 2021 on 10 stocks
|
5/5/2016 | SP | JPMorgan plans autocallable contingent interest notes on three stocks
|
5/5/2016 | SP | JPMorgan plans 9% trigger autocallable contingent yield notes on Gilead
|
5/3/2016 | SP | JPMorgan plans autocallable contingent interest notes linked to Gilead
|
4/19/2016 | SP | New Issue: GS Finance sells $2.83 million contingent income autocallables linked to Gilead
|
4/13/2016 | SP | New Issue: UBS prices $379,624 4.97% trigger yield optimization notes linked to Gilead
|
4/8/2016 | SP | GS Finance plans one-year contingent income autocallables on Gilead
|
4/5/2016 | PP | Market Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity; Tesla firmer
|
4/5/2016 | CV | Market Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity; Tesla firmer
|
4/5/2016 | CV | Market Commentary: Morning Commentary: Convertibles steady despite slip in stocks; Gilead active ahead of maturity
|
3/24/2016 | SP | New Issue: Wells Fargo prices $5.23 million of 0.125% notes tied to pharma stocks
|
3/22/2016 | SP | Wells Fargo to price 0.125% notes linked to four pharma stocks
|
3/4/2016 | CV | Gilead Sciences will settle 1.625% convertible notes due 2016 in cash
|
3/3/2016 | SP | New Issue: HSBC prices $8.58 million income notes linked to basket of 20 stocks
|
2/29/2016 | SP | New Issue: JPMorgan prices $2.03 million buffered return optimization notes linked to 10 stocks
|
2/18/2016 | SP | New Issue: Credit Suisse sells $1.01 million contingent coupon autocallable notes on Gilead
|
2/12/2016 | SP | HSBC plans to price income notes linked to basket of 20 common stocks
|
2/9/2016 | SP | Credit Suisse plans contingent coupon autocallables linked to Gilead
|
2/2/2016 | SP | JPMorgan to price callable reverse exchangeables linked to Gilead
|
2/2/2016 | SP | UBS plans return optimization notes due 2017 with cap tied to stocks
|
12/3/2015 | SP | New Issue: Credit Suisse prices $8.8 million trigger phoenix autocallables linked to Gilead Sciences
|
12/1/2015 | SP | New Issue: Deutsche Bank prices $5.25 million of securities due 2016 tied to Gilead
|
11/23/2015 | SP | Credit Suisse to price trigger phoenix autocallables linked to Gilead
|
10/28/2015 | SP | New Issue: Citigroup prices $1.25 million contingent coupon autocallables linked to Gilead Sciences
|
10/23/2015 | SP | New Issue: RBC prices $2.7 million bullish barrier enhanced notes on five stocks
|
10/20/2015 | SP | New Issue: RBC prices $410,000 bullish barrier enhanced notes linked to five stocks
|
10/19/2015 | SP | RBC plans 0% bullish barrier enhanced notes on basket of five stocks
|
10/15/2015 | SP | RBC plans bullish barrier enhanced return notes on five stocks
|
10/14/2015 | SP | New Issue: JPMorgan prices $503,000 autocallable reverse exchangeables linked to Gilead Sciences
|
10/8/2015 | SP | Citigroup plans contingent coupon autocallables on Gilead Sciences
|
10/2/2015 | PP | Market Commentary: Convertibles decline on weak jobs report, pare losses by the bell; liquidity constrained
|
10/2/2015 | CV | Market Commentary: Convertibles decline on weak jobs report, pare losses by the bell; liquidity constrained
|
9/30/2015 | SP | JPMorgan plans autocallable reverse exchangeables linked to Gilead
|
9/17/2015 | SP | New Issue: JPMorgan prices $1.21 million autocallable reverse exchangeables linked to Gilead Sciences
|
9/11/2015 | IG | Market Commentary: Morning Commentary: Gilead Sciences mostly stronger in secondary market; Home Depot unchanged
|
9/10/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/10/2015 | IG | New Issue: Gilead Sciences details $10 billion six-part sale of senior notes
|
9/9/2015 | IG | New Issue: Gilead Sciences prices $10 billion of notes in six tranches
|
9/9/2015 | EMHYMUPFPV | Market Commentary: Primary surge continues; Gilead does $10 billion deal; Intel, Wal-Mart tighten
|
9/9/2015 | IG | Market Commentary: Primary surge continues; Gilead does $10 billion deal; Intel, Wal-Mart tighten
|
9/9/2015 | IG | Gilead Sciences launches $10 billion of senior notes in six tranches
|
9/9/2015 | CVIG | S&P rates Gilead notes A-
|
9/9/2015 | CVIG | Moody’s rates Gilead notes A3
|
9/9/2015 | IG | Gilead Sciences preparing to sell senior notes in six tranches
|
9/8/2015 | SP | JPMorgan plans 8%-10% autocallable reverse exchangeables on Gilead
|
9/4/2015 | SP | New Issue: HSBC prices $3.17 million contingent income barrier autocallables linked to Gilead Sciences
|
9/3/2015 | SP | New Issue: JPMorgan prices $1.06 million autocallable reverse exchangeables linked to Gilead Sciences
|
9/1/2015 | SP | New Issue: JPMorgan prices $10.75 million 7% airbag autocallables linked to Gilead
|
8/31/2015 | SP | HSBC plans contingent income barrier autocallables tied to Gilead
|
8/25/2015 | SP | JPMorgan plans 6%-8.5% airbag autocallable notes linked to Gilead
|
8/21/2015 | SP | JPMorgan plans 8%-10% autocallable reverse exchangeables on Gilead
|
8/19/2015 | SP | New Issue: JPMorgan sells $4.4 million trigger phoenix autocallables on Gilead
|
8/17/2015 | SP | New Issue: UBS prices $110,000 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
8/14/2015 | SP | New Issue: UBS prices $166,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/11/2015 | SP | JPMorgan plans to price trigger phoenix autocallables tied to Gilead
|
8/6/2015 | SP | New Issue: UBS prices $160,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/5/2015 | SP | New Issue: Morgan Stanley prices $6.5 million contingent income autocallables linked to Gilead
|
7/28/2015 | SP | New Issue: JPMorgan prices $1.25 million autocallable contingent interest notes linked to Gilead Sciences
|
7/24/2015 | SP | New Issue: JPMorgan prices $10.8 million autocallable reverse exchangeables linked to Celgene, Gilead
|
7/24/2015 | SP | Morgan Stanley plans contingent income autocallables on Gilead Sciences
|
7/22/2015 | SP | JPMorgan plans contingent interest autocallable notes linked to Gilead
|
7/21/2015 | SP | New Issue: Barclays sells $11.09 million contingent income autocallables on Gilead
|
7/14/2015 | SP | JPMorgan plans autocallable reverse exchangeables on Celgene, Gilead
|
7/9/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/9/2015 | SP | Barclays plans contingent income autocallables tied to Gilead Sciences
|
7/8/2015 | SP | New Issue: Credit Suisse prices $731,000 7.5% autocallable reverse convertibles tied to Gilead
|
7/2/2015 | SP | New Issue: Deutsche prices $4.13 million contingent absolute return autocallables on Gilead
|
6/25/2015 | SP | New Issue: UBS prices $343,000 trigger autocallables linked to Gilead Sciences
|
6/25/2015 | SP | New Issue: UBS prices $410,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/24/2015 | SP | Deutsche Bank plans contingent absolute return notes linked to Gilead
|
6/23/2015 | SP | New Issue: UBS prices $155,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/22/2015 | SP | Credit Suisse plans 7%-9% reverse convertible autocallables on Gilead
|
6/16/2015 | SP | New Issue: UBS prices $2.94 million contingent income autocallables tied to Gilead
|
6/4/2015 | SP | UBS plans one-year contingent income autocallables linked to Gilead
|
6/2/2015 | SP | New Issue: JPMorgan prices $1.53 million autocallable contingent interest notes linked to Gilead Sciences
|
6/2/2015 | SP | New Issue: JPMorgan prices $3.27 million autocallable contingent interest notes linked to stocks
|
6/1/2015 | SP | New Issue: Credit Suisse prices $2.26 million 7.5% autocallable reverse convertibles on Gilead
|
5/29/2015 | SP | New Issue: RBC prices $1 million trigger phoenix autocallable notes linked to Celgene, Gilead
|
5/27/2015 | SP | JPMorgan plans autocallable contingent interest notes linked to Gilead
|
5/20/2015 | SP | JPMorgan plans contingent interest autocallable notes linked to Gilead
|
5/19/2015 | SP | New Issue: JPMorgan prices $464,000 autocallable reverse exchangeables on Gilead
|
5/15/2015 | SP | JPMorgan plans contingent income autocallables tied to Gilead Sciences
|
5/13/2015 | SPSW | May kicks off on good note with $446 million priced in 112 offerings; agents sell repeat deals
|
5/8/2015 | SP | New Issue: UBS prices $503,650 return optimization securities on Gilead Sciences
|
5/5/2015 | SP | Credit Suisse plans autocallable reverse convertibles linked to Gilead
|
5/5/2015 | SP | JPMorgan plans autocallable reverse exchangeable notes tied to Gilead
|
4/30/2015 | SP | Market Commentary: Citi prices $1.27 million autocallables tied to stocks with eye-catching 31% contingent coupon
|
4/29/2015 | SP | New Issue: JPMorgan prices $2.07 million autocallable contingent interest notes linked to stocks
|
4/28/2015 | SP | New Issue: Morgan Stanley prices $6.48 million contingent income autocallables linked to Gilead
|
4/17/2015 | SP | New Issue: JPMorgan prices $389,000 autocallable 7% reverse exchangeables linked to Gilead
|
4/16/2015 | SP | Morgan Stanley plans contingent income autocallables on Gilead Sciences
|
4/14/2015 | SP | New Issue: UBS prices $129,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/14/2015 | SP | New Issue: JPMorgan prices $3.68 million autocallable contingent interest notes linked to Gilead Sciences
|
4/14/2015 | SP | New Issue: JPMorgan prices $7.25 million 9.75% autocallable reverse exchangeables on two stocks
|
4/8/2015 | SP | New Issue: UBS prices $379,805 4.37% trigger yield optimization notes linked to Gilead Sciences
|
4/8/2015 | SP | JPMorgan plans 7%-9% autocallable reverse exchangeable notes on Gilead
|
4/7/2015 | SP | JPMorgan plans contingent interest autocallables on Gilead Sciences
|
4/7/2015 | SP | JPMorgan plans autocallable reverse exchangeables tied to two stocks
|
4/2/2015 | SP | New Issue: JPMorgan prices $2.35 million autocallable contingent interest notes linked to stocks
|
3/31/2015 | SP | New Issue: JPMorgan prices $3.17 million trigger phoenix autocallables linked to Gilead
|
3/24/2015 | SP | JPMorgan plans trigger phoenix autocallables linked to Gilead
|
3/11/2015 | SP | New Issue: UBS prices $5.83 million contingent income autocallables tied to Gilead
|
3/6/2015 | SP | New Issue: UBS prices $113,000 trigger autocallables linked to Gilead Sciences
|
3/4/2015 | SP | New Issue: Citigroup prices $1 million autocallable contingent coupon securities on stocks
|
3/3/2015 | SP | New Issue: JPMorgan prices $1.7 million autocallable reverse exchangeable notes linked to Gilead
|
3/2/2015 | SP | UBS plans to price contingent income autocallables on Gilead
|
2/26/2015 | SP | New Issue: Morgan Stanley prices $2.62 million contingent income autocallable securities on Gilead
|
2/24/2015 | SP | JPMorgan plans autocallable reverse exchangeable notes on Gilead
|
2/20/2015 | SP | New Issue: JPMorgan prices $983,000 8% autocallable reverse convertibles linked to Gilead
|
2/13/2015 | SP | New Issue: UBS prices $205,000 trigger return optimization securities linked to Gilead Sciences
|
2/12/2015 | SP | New Issue: UBS prices $532,000 trigger return optimization securities linked to Gilead Sciences
|
2/10/2015 | SP | New Issue: UBS prices $468,000 trigger return optimization securities linked to Gilead Sciences
|
2/10/2015 | SP | JPMorgan plans autocallable reverse exchangeable notes on Gilead
|
2/9/2015 | SP | New Issue: UBS prices $129,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
2/5/2015 | SP | New Issue: UBS prices $156,942 7.68% trigger yield optimization notes linked to Gilead Sciences
|
2/4/2015 | PP | Market Commentary: Microchip plans $1 billion new deal; Gilead Sciences in focus; Brocade lifts with shares
|
2/4/2015 | CV | Market Commentary: Microchip plans $1 billion new deal; Gilead Sciences in focus; Brocade lifts with shares
|
2/4/2015 | SP | New Issue: UBS prices $100,000 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
2/4/2015 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
2/4/2015 | SP | New Issue: UBS prices $99,906 8.03% trigger yield optimization notes linked to Gilead Sciences
|
2/4/2015 | SP | New Issue: UBS prices $150,000 trigger return optimization securities linked to Gilead Sciences
|
2/4/2015 | CV | Market Commentary: Morning Commentary: Gilead Sciences in focus after earnings; Brocade convertibles up with shares
|
2/3/2015 | SP | New Issue: UBS prices $108,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
2/2/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/29/2015 | SP | New Issue: Deutsche Bank prices $2.13 million trigger phoenix autocallables linked to Gilead Sciences
|
1/21/2015 | SP | New Issue: Credit Suisse prices $5.16 million trigger phoenix autocallables linked to Gilead Sciences
|
1/21/2015 | SP | New Issue: Credit Suisse prices $1.89 million contingent coupon autocallables on Gilead Sciences
|
1/13/2015 | SP | Credit Suisse plans contingent coupon autocallables linked to Gilead
|
1/13/2015 | SP | New Issue: RBC prices $7.07 million phoenix autocallable notes on Gilead Sciences
|
1/12/2015 | SP | Credit Suisse plans trigger phoenix autocallables on Gilead Sciences
|
1/8/2015 | SP | RBC to price phoenix autocallable notes linked to Gilead Sciences
|
12/30/2014 | SP | New Issue: Barclays prices $1.5 million autocallable notes linked to two stocks
|
12/29/2014 | SP | New Issue: JPMorgan prices $3.95 million 8% reverse exchangeables linked to Gilead Sciences
|
12/24/2014 | EMHYMUPFPV | Market Commentary: Investment-grade bond market activity slows; Amazon improves; credit spreads modestly better
|
12/24/2014 | IG | Market Commentary: Investment-grade bond market activity slows; Amazon improves; credit spreads modestly better
|
12/24/2014 | CV | Market Commentary: American Realty bonds add a point with shares lower; market quiet ahead of holiday
|
12/24/2014 | IG | Market Commentary: Morning Commentary: Investment-grade bonds mixed in thin trade; Amazon long bonds firm
|
12/24/2014 | SP | New Issue: Citigroup prices $2.18 million contingent coupon autocallables on Gilead Sciences
|
12/23/2014 | PP | Market Commentary: Trading tapers before holiday; Gilead Sciences steady on hedge; Royal Gold better to buy
|
12/23/2014 | CV | Market Commentary: Trading tapers before holiday; Gilead Sciences steady on hedge; Royal Gold better to buy
|
12/23/2014 | SP | New Issue: UBS prices $117,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/22/2014 | PP | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
12/22/2014 | CV | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
12/22/2014 | SP | New Issue: UBS prices $4.36 million contingent absolute return autocallables tied to Gilead
|
12/22/2014 | CV | Market Commentary: Morning Commentary: Gilead lower outright after Express Scripts-AbbVie deal; MGM weaker again
|
12/18/2014 | SP | JPMorgan plans 8% single observation reverse exchangeables on Gilead
|
12/17/2014 | SP | New Issue: RBC prices $6.23 million contingent absolute return autocallables linked to Gilead
|
12/15/2014 | SP | UBS plans contingent absolute return autocallables on Gilead Sciences
|
12/10/2014 | SP | RBC plans contingent absolute return autocallables tied to Gilead
|
12/10/2014 | SP | Citigroup to price contingent coupon autocallables on Gilead Sciences
|
12/9/2014 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/9/2014 | IG | Market Commentary: Morning Commentary: High-grade bonds soften; Morgan Stanley, Gilead Sciences notes ease
|
12/5/2014 | SP | New Issue: UBS prices $220,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/1/2014 | SP | New Issue: JPMorgan prices $3.73 million auto callable contingent interest notes linked to Gilead Sciences
|
12/1/2014 | SP | New Issue: RBC prices $2.12 million buffered optimization notes tied to health care stocks
|
12/1/2014 | SP | New Issue: Barclays prices $13.78 million trigger phoenix autocallables on Gilead Sciences
|
11/26/2014 | SP | New Issue: Barclays prices $26.46 million 14-month Accelerated Return Notes tied to biotech stocks
|
11/25/2014 | SP | JPMorgan plans contingent interest autocallables on Gilead Sciences
|
11/24/2014 | SP | New Issue: Morgan Stanley prices $2.69 million contingent income autocallable securities on Gilead
|
11/24/2014 | SP | New Issue: Credit Suisse prices $2.93 million of 9.25% autocallable reverse convertibles on Gilead
|
11/24/2014 | SP | New Issue: UBS prices $208,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/24/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/21/2014 | SP | New Issue: CIBC prices $2.7 million 8.05% autocallable securities tied to Gilead
|
11/20/2014 | SP | CIBC plans 8.05% autocallable equity-linked securities tied to Gilead
|
11/20/2014 | SP | Barclays plans trigger phoenix autocallables linked to Gilead Sciences
|
11/19/2014 | SP | New Issue: UBS prices $149,928 7.37% trigger yield optimization notes linked to Gilead Sciences
|
11/19/2014 | SP | Market Commentary: HSBC’s $39.75 million 10% STEP Income tied to Gilead offer bullish bet on stock, no barrier
|
11/19/2014 | SPSW | November shows weakness with volume down by a third, but sources say month is not over yet
|
11/19/2014 | SP | New Issue: UBS prices $100,000 airbag return optimization securities linked to Gilead Sciences
|
11/18/2014 | SP | New Issue: HSBC prices $39.75 million 10% STEP Income Securities on Gilead Sciences
|
11/18/2014 | SP | Barclays plans 14-month Accelerated Return Notes tied to biotech stocks
|
11/18/2014 | IG | Market Commentary: Morning Commentary: High-grade spreads firm as primary heats up; Gilead, Walgreens improve
|
11/14/2014 | IG | Market Commentary: Morning Commentary: Investment-grade credit spreads soft; Citigroup flat; Gilead tightens
|
11/13/2014 | SP | Morgan Stanley plans contingent income autocallables tied to Gilead
|
11/13/2014 | SP | New Issue: RBC prices $14.85 million 8.24% airbag autocallables linked to Gilead
|
11/12/2014 | EMHYMUPFPV | Market Commentary: Ten deals hit high-grade market following holiday; spreads flat; Eastman Chemical mixed
|
11/12/2014 | IG | Market Commentary: Ten deals hit high-grade market following holiday; spreads flat; Eastman Chemical mixed
|
11/12/2014 | IG | New Issue: Gilead Sciences prices $4 billion of senior notes in three tranches
|
11/12/2014 | CVIG | S&P: Gilead Sciences notes A-
|
11/12/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/12/2014 | CVIG | Moody’s provides A3 to Gilead notes
|
11/12/2014 | IG | Gilead Sciences preparing to sell senior notes in three tranches
|
11/11/2014 | CVIG | Moody’s upgrades Gilead
|
11/7/2014 | SP | Credit Suisse plans autocallable reverse convertibles tied to Gilead
|
11/5/2014 | SP | HSBC to price 10% STEP Income Securities linked to Gilead Sciences
|
11/5/2014 | SP | RBC to price 6.1%-8.1% airbag autocallables linked to Gilead Sciences
|
11/3/2014 | SP | New Issue: UBS prices $185,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/31/2014 | SP | HSBC to price 10% autocallable yield notes linked to three stocks
|
10/31/2014 | SP | New Issue: UBS prices $375,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/30/2014 | SP | New Issue: UBS prices $170,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/30/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/29/2014 | SP | New Issue: UBS prices $195,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/28/2014 | SP | New Issue: UBS prices $215,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/17/2014 | SP | New Issue: UBS prices $233,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/16/2014 | SP | New Issue: UBS prices $253,500 contingent absolute return autocallable optimization securities linked to Gilead Sciences
|
10/15/2014 | SP | New Issue: Barclays prices $8.58 million contingent income autocallables on Gilead
|
10/10/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/10/2014 | SP | New Issue: UBS prices $276,500 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/7/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/7/2014 | SP | Barclays plans contingent income autocallable notes linked to Gilead
|
10/3/2014 | SP | New Issue: UBS prices $252,000 contingent absolute return autocallables linked to Gilead
|
10/3/2014 | SP | New Issue: UBS prices $120,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/3/2014 | SP | New Issue: UBS prices $124,521 8.33% trigger yield optimization notes linked to Gilead Sciences
|
10/1/2014 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/30/2014 | SP | New Issue: UBS prices $4.98 million contingent absolute return autocallables linked to Gilead Sciences
|
9/30/2014 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/24/2014 | SP | New Issue: UBS prices $310,000 contingent absolute return autocallables linked to Gilead Sciences
|
9/24/2014 | SP | New Issue: UBS prices $169,000 trigger autocallables linked to Gilead Sciences
|
9/22/2014 | SP | UBS plans contingent absolute return autocallables linked to Gilead
|
9/19/2014 | SP | New Issue: HSBC prices $1.1 million autocallable contingent interest barrier notes on Gilead Sciences
|
9/18/2014 | PP | Market Commentary: PDL BioPharma drops after auditor news; Gilead remains weaker; secondary softness persists
|
9/18/2014 | CV | Market Commentary: PDL BioPharma drops after auditor news; Gilead remains weaker; secondary softness persists
|
9/18/2014 | SP | New Issue: UBS prices $365,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/17/2014 | SP | New Issue: JPMorgan prices $7.77 million contingent absolute return autocallables tied to Gilead
|
9/16/2014 | SP | New Issue: UBS prices $167,040 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/12/2014 | SP | New Issue: UBS prices $475,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/12/2014 | SP | New Issue: UBS prices $500,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/12/2014 | SP | New Issue: Morgan Stanley prices $1.41 million contingent income autocallables linked to Gilead Sciences
|
9/11/2014 | SP | New Issue: UBS prices $118,080 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/10/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/9/2014 | SP | JPMorgan plans contingent absolute return autocallables on Gilead
|
9/9/2014 | SP | New Issue: JPMorgan prices $1.39 million auto callable contingent interest notes linked to Gilead Sciences
|
9/9/2014 | SP | Morgan Stanley plans contingent income autocallables on Gilead Sciences
|
9/5/2014 | SP | New Issue: UBS prices $140,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/5/2014 | SP | New Issue: UBS prices $99,881 5.06% trigger yield optimization notes linked to Gilead Sciences
|
9/4/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/4/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/4/2014 | SP | JPMorgan plans autocallable contingent interest notes on Gilead
|
9/2/2014 | PP | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
9/2/2014 | SP | New Issue: UBS prices $580,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/28/2014 | SP | New Issue: JPMorgan sells $1.93 million 8.25% autocall reverse exchangeables on Gilead
|
8/28/2014 | SP | New Issue: JPMorgan sells $1.93 million 8.25% autocall reverse exchangeables on Gilead
|
8/27/2014 | SP | New Issue: Citigroup sells $3.67 million contingent coupon autocallables on Gilead
|
8/20/2014 | SP | New Issue: UBS prices $1 million trigger autocallables linked to Gilead Sciences
|
8/19/2014 | SP | New Issue: JPMorgan prices $1.38 million contingent interest autocallables linked to Gilead
|
8/18/2014 | PP | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
8/18/2014 | CV | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
8/18/2014 | CV | Market Commentary: Morning Commentary: Priceline off a bit in early trade; Gilead active, less 1.5 points to parity
|
8/15/2014 | SP | New Issue: UBS prices $195,900 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/14/2014 | SP | JPMorgan plans 8%-10% autocallable reverse exchangeables tied to Gilead
|
8/12/2014 | SP | New Issue: RBC prices $1.94 million phoenix autocallable notes on Gilead Sciences
|
8/12/2014 | SP | JPMorgan plans autocallable contingent interest notes on Gilead
|
8/5/2014 | SP | RBC plans to price phoenix autocallables linked to Gilead Sciences
|
8/4/2014 | SP | Citigroup plans contingent coupon autocallables tied to Gilead Sciences
|
7/31/2014 | SP | New Issue: UBS prices $118,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/24/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/15/2014 | SP | New Issue: UBS prices $6.48 million airbag phoenix autocallable notes linked to Gilead Sciences
|
7/15/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/9/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/9/2014 | SP | JPMorgan plans to price return notes linked to basket of 16 stocks
|
7/8/2014 | SP | UBS plans airbag phoenix autocallable notes linked to Gilead Sciences
|
7/8/2014 | SP | New Issue: Morgan Stanley prices $3.53 million contingent income auto-callable securities linked to Gilead Sciences
|
6/30/2014 | SP | New Issue: UBS prices $2.49 million contingent absolute return autocallables linked to Gilead
|
6/27/2014 | SP | Morgan Stanley plans contingent income autocallables linked to Gilead
|
6/25/2014 | SP | UBS plans contingent absolute return autocallables linked to Gilead
|
6/24/2014 | SP | New Issue: UBS prices $605,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/24/2014 | SP | New Issue: UBS prices $259,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/24/2014 | SP | New Issue: UBS prices $330,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/20/2014 | SP | JPMorgan plans capped contingent buffered notes on Gilead Sciences
|
6/17/2014 | SP | New Issue: UBS prices $170,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/16/2014 | SP | New Issue: UBS prices $140,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/9/2014 | SP | New Issue: UBS prices $463,000 trigger autocallables linked to Gilead Sciences
|
5/30/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
5/22/2014 | SP | New Issue: Credit Suisse prices $2.03 million 8% autocallable reverse convertibles on Gilead
|
5/16/2014 | SP | Correction: Cusip for Credit Suisse's RevCons on Gilead is 22547QN85
|
5/13/2014 | SP | Credit Suisse plans autocallable reverse convertibles tied to Gilead
|
5/13/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
5/7/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/30/2014 | SP | New Issue: RBC prices $2.86 million 7.6% reverse convertibles linked to Gilead, eBay
|
4/28/2014 | SP | New Issue: UBS prices $170,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/25/2014 | SP | New Issue: UBS prices $1 million trigger autocallables linked to Gilead Sciences
|
4/23/2014 | SP | Unrelenting interest in equity helps volume grow by 15.5% to $12.61 billion for year to date
|
4/22/2014 | CV | Market Commentary: Earnings drive convertibles action; Medidata tanks outright, adds on hedge; Rambus in line
|
4/21/2014 | SP | New Issue: Barclays prices $1.77 million phoenix autocallable notes tied to Gilead
|
4/17/2014 | SP | New Issue: UBS prices $121,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/16/2014 | SP | Barclays plans to price phoenix autocallable notes linked to Gilead
|
4/16/2014 | SP | New Issue: Barclays prices $19.72 million 10% Yeelds linked to Gilead Sciences
|
4/16/2014 | SP | New Issue: Barclays prices $15.54 million 3% Yeelds linked to Gilead Sciences
|
4/15/2014 | SP | New Issue: JPMorgan prices $2.06 million autocallable contingent interest notes on Gilead Sciences
|
4/14/2014 | SP | New Issue: UBS prices $333,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/11/2014 | SP | New Issue: UBS prices $374,852 4.8% trigger yield optimization notes linked to Gilead Sciences
|
4/9/2014 | CV | Market Commentary: WellPoint flat to higher in active trade; larger, higher-grade issues trade; RPM in focus
|
4/9/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/8/2014 | SP | JPMorgan to price autocallable contingent interest notes on Gilead
|
4/3/2014 | SP | New Issue: UBS prices $353,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
4/2/2014 | SP | New Issue: JPMorgan prices $5.07 million autocallable contingent interest notes on Gilead Sciences
|
4/2/2014 | SP | New Issue: RBC prices $1 million 7.5% reverse convertibles linked to Gilead Sciences
|
4/1/2014 | SP | New Issue: Credit Suisse prices $2.02 million 8.4% autocallable reverse convertibles on Gilead
|
4/1/2014 | SP | New Issue: JPMorgan sells $10.59 million contingent income autocallables on Gilead
|
4/1/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/31/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/28/2014 | CV | Gilead opts to settle conversions of 1% senior notes due 2014 in cash
|
3/28/2014 | SP | Market Commentary: JPMorgan's reverse exchangeables linked to Gilead show below-average value due to margins
|
3/26/2014 | SP | JPMorgan to price 9.5%-11.5% reverse exchangeables linked to Gilead
|
3/25/2014 | SP | New Issue: JPMorgan prices $5.39 million autocallable contingent interest notes on Gilead Sciences
|
3/25/2014 | SP | JPMorgan plans autocallable contingent interest notes linked to Gilead
|
3/25/2014 | SP | New Issue: JPMorgan prices $7.52 million contingent absolute return autocallables on Gilead
|
3/24/2014 | SP | New Issue: UBS prices $130,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/21/2014 | CV | Market Commentary: Convertibles quiet; National Health lags dollar neutral; Navistar 'holds in;' Sterlite gains
|
3/21/2014 | SP | JPMorgan plans contingent income autocallables tied to Gilead Sciences
|
3/19/2014 | SP | JPMorgan plans contingent absolute return autocallables tied to Gilead
|
3/18/2014 | SP | JPMorgan plans autocallable contingent interest notes linked to Gilead
|
3/18/2014 | SP | New Issue: Barclays prices $4.03 million phoenix autocallables on Gilead Sciences
|
3/18/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/18/2014 | SP | New Issue: UBS prices $566,500 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/18/2014 | SP | New Issue: UBS prices $577,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/18/2014 | SP | Credit Suisse plans 8.25% autocallable reverse convertibles on Gilead
|
3/17/2014 | SP | New Issue: UBS prices $99,971 4.88% trigger yield optimization notes linked to Gilead Sciences
|
3/14/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/13/2014 | SP | Barclays plans phoenix autocallable notes linked to Gilead Sciences
|
3/12/2014 | SP | New Issue: UBS prices $305,000 contingent absolute return autocallables linked to Gilead Sciences
|
3/11/2014 | SP | New Issue: JPMorgan prices $2.36 million autocallable contingent interest notes tied to Gilead
|
3/5/2014 | IG | New Issue: Gilead Sciences details $4 billion sale of senior notes in three maturities
|
3/4/2014 | IG | New Issue: Gilead Sciences prices $4 billion senior notes in three maturities
|
3/4/2014 | IG | Market Commentary: Packed primary sees Gilead, RBC, Coca-Cola price; Aetna, Air Lease, Pitney Bowes firm
|
3/4/2014 | SP | JPMorgan plans autocallable contingent interest notes linked to Gilead
|
3/4/2014 | CVIG | Moody's rates Gilead's notes Baa1
|
3/4/2014 | SP | New Issue: Barclays prices $5.44 million phoenix autocallables linked to Gilead
|
3/4/2014 | CVIG | S&P assigns Gilead debt A-
|
3/4/2014 | IG | Gilead Sciences to sell senior notes in three maturities
|
2/26/2014 | SP | Barclays plans phoenix autocallable notes linked to Gilead Sciences
|
2/26/2014 | SP | New Issue: JPMorgan prices $3.24 million airbag phoenix autocallables on Gilead Sciences
|
2/25/2014 | SP | New Issue: UBS prices $109,806 8.61% trigger yield optimization notes linked to Gilead Sciences
|
2/20/2014 | SP | New Issue: UBS prices $579,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
2/19/2014 | SP | JPMorgan plans airbag phoenix autocallables linked to Gilead Sciences
|
2/11/2014 | CV | Market Commentary: Planned AMAG looks cheap; Canadian Solar launches; WebMD slips outright, adds on hedge
|
2/5/2014 | SP | New Issue: Credit Suisse prices $1.09 million 8.5% autocallable reverse convertibles linked to Gilead
|
1/31/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/27/2014 | SP | New Issue: UBS prices $174,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/24/2014 | SP | Credit Suisse plans 8% autocallable reverse convertibles on Gilead
|
1/22/2014 | SP | New Issue: RBC prices $2.12 million trigger phoenix autocallable securities tied to Gilead Sciences
|
1/22/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/17/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/16/2014 | SP | New Issue: UBS prices $525,000 trigger autocallables linked to Gilead Sciences
|
1/14/2014 | SP | New Issue: UBS prices $15.01 million 8.6% airbag autocallables linked to Gilead Sciences
|
1/9/2014 | SP | New Issue: UBS prices $336,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/8/2014 | SP | New Issue: UBS prices $335,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
1/2/2014 | SP | UBS to price 6.6%-8.6% airbag autocallables linked to Gilead Sciences
|
12/18/2013 | SP | New Issue: UBS prices $254,547 9.34% trigger yield optimization notes linked to Gilead Sciences
|
12/17/2013 | SP | New Issue: Barclays prices $744,000 phoenix autocallables tied to Gilead Sciences
|
12/17/2013 | SP | New Issue: Credit Suisse prices $1.56 million 9% autocallable reverse convertibles on Gilead
|
12/16/2013 | SP | New Issue: UBS prices $197,976 8.33% trigger yield optimization notes linked to Gilead Sciences
|
12/16/2013 | SP | New Issue: UBS prices $680,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/13/2013 | SP | New Issue: JPMorgan prices $1 million autocallable contingent interest notes linked to Gilead Sciences
|
12/10/2013 | SP | New Issue: Credit Suisse prices $20.06 million 12% equity-linked notes on Gilead
|
12/10/2013 | SP | New Issue: Deutsche Bank prices $1.43 million phoenix autocallables tied to Gilead
|
12/10/2013 | SP | New Issue: UBS prices $524,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/10/2013 | SP | Barclays plans phoenix autocallable notes linked to Gilead Sciences
|
12/9/2013 | CVIG | Moody's: Gilead view to positive
|
12/9/2013 | SP | Credit Suisse plans 9% autocallable reverse convertibles on Gilead
|
12/4/2013 | SP | New Issue: Credit Suisse prices $450,000 contingent coupon autocallables linked to five stocks
|
12/4/2013 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
12/4/2013 | SP | Deutsche Bank plans phoenix autocallable securities on Gilead Sciences
|
12/3/2013 | SP | New Issue: Barclays prices $1.5 million phoenix autocallables on Gilead Sciences
|
11/26/2013 | SP | New Issue: JPMorgan prices $1.05 million autocallable contingent interest notes linked to Gilead Sciences
|
11/20/2013 | SP | New Issue: Citigroup prices $5.31 million 7.67% airbag autocallables linked to Gilead Sciences
|
11/19/2013 | SP | New Issue: JPMorgan prices $3.2 million contingent interest autocallables on Gilead Sciences
|
11/19/2013 | SP | JPMorgan plans autocallable contingent interest notes tied to Gilead
|
11/13/2013 | SP | Citigroup to price 6%-7.7% airbag autocallables linked to Gilead
|
11/13/2013 | SP | New Issue: UBS prices $564,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
11/12/2013 | SP | JPMorgan plans autocallable contingent interest notes tied to Gilead
|
10/30/2013 | SP | New Issue: Credit Suisse sells $722,000 7% autocallable reverse convertible notes on Gilead Sciences
|
10/21/2013 | CV | Market Commentary: Convertibles 'tread water' ahead of data, earnings reports; planned Crown Castle deal eyed
|
10/17/2013 | SP | Credit Suisse plans 7% one-year autocallable reverse convertibles linked to Gilead Sciences
|
10/11/2013 | SP | New Issue: UBS prices $127,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
10/8/2013 | SP | New Issue: Citigroup prices $4.93 million 7.75% airbag autocallable yield notes tied to Gilead Sciences
|
10/2/2013 | SP | Citigroup plans 6%-7.6% airbag autocallables linked to Gilead Sciences
|
9/25/2013 | SP | New Issue: UBS prices $311,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/20/2013 | SP | New Issue: UBS prices $185,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
9/17/2013 | SP | New Issue: UBS prices $110,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/28/2013 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
8/2/2013 | SP | New Issue: UBS prices $162,720 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/26/2013 | CV | Market Commentary: Level 3 strong after earnings; Tesla extends gains; Goodrich better; American Realty weak
|
7/23/2013 | SP | New Issue: UBS prices $129,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
7/8/2013 | CV | Market Commentary: Convertibles firmer; shorter-dated issues holding up; Peabody, longer-dated names weaker
|
6/25/2013 | SP | New Issue: UBS prices $205,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/21/2013 | CV | Market Commentary: Convertibles heavier as fear dominates tone; bank preferreds down; IG paper lower in line
|
6/12/2013 | SP | Deutsche Bank plans trigger phoenix autocallables on Gilead Sciences
|
6/12/2013 | SP | New Issue: UBS prices $99,986 7.43% trigger yield optimization notes linked to Gilead Sciences
|
6/11/2013 | SP | New Issue: UBS prices $221,000 trigger autocallables linked to Gilead Sciences
|
6/11/2013 | SP | New Issue: UBS prices $306,000 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
6/4/2013 | SP | New Issue: UBS prices $102,130 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
5/8/2013 | SP | Bid for unprotected leveraged notes, autocallables goes on as equity markets set new highs
|
5/8/2013 | SP | New Issue: UBS prices $109,500 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
5/3/2013 | SP | New Issue: Credit Suisse prices $37.95 million 8% equity-linked notes linked to Gilead Sciences
|
4/22/2013 | CV | Market Commentary: Integra LifeSciences flat to lower; Vertex quiet after surge; Intel, Microsoft in trade
|
4/8/2013 | SP | New Issue: UBS prices $123,800 trigger phoenix autocallable optimization securities linked to Gilead Sciences
|
3/12/2013 | SP | New Issue: UBS prices $906,500 trigger phoenix autocallables on Gilead Sciences
|
3/5/2013 | SP | UBS plans trigger phoenix autocallable securities on Gilead Sciences
|
2/4/2013 | CV | Market Commentary: Gilead Sciences steady ahead of earnings; Medtronic active; SandRidge lower on trust news
|
1/15/2013 | CV | Market Commentary: Amgen sees sellers ahead of maturity; Gilead Ds better; Lennar slips; Pacira to price
|
1/14/2013 | CV | Market Commentary: Dendreon adds outright; InterMune intends to price notes, shares; Lennar earnings on tap
|
12/24/2012 | CV | Market Commentary: Convertibles quiet in shortened, pre-holiday session; Greatbatch trades higher on call
|
12/3/2012 | CV | Market Commentary: Teva trades after disappointing outlook; Volcano's planned $350 million convertible on tap
|
11/30/2012 | CV | Market Commentary: VeriSign drops outright in active trade but improves on hedge; larger, liquid names active
|
11/27/2012 | CV | Market Commentary: Convertibles thinly traded; NetApp steady after Monday's slip; DryShips extends gains
|
11/26/2012 | CV | Market Commentary: DryShips jumps as rebound continues; Knight Capital slightly higher; Trina Solar in focus
|
11/16/2012 | CV | Market Commentary: DryShips, CEDC extend drops; new paper mixed, AK Steel falls to 96; Vector pushes over 104
|
11/13/2012 | CV | Market Commentary: Gilead trades mixed on data; Vertex in line; CEDC sinks in light trade; GT Advanced down
|
11/9/2012 | CV | Market Commentary: James River, Alpha Natural little moved as shares fall; SandRidge flat to slightly higher
|
10/24/2012 | CV | Market Commentary: NuVasive trades flattish as shares jump; Navistar gains as shares slip; EMC paper active
|
10/23/2012 | CV | Market Commentary: RadioShack strengthens with buyback news; Gilead 'up small' ahead of earnings; AMD lower
|
10/17/2012 | CV | Market Commentary: Intel flat to lower outright, up on hedge; Knight firm; Stillwater, WellPoint doing well
|
10/9/2012 | CV | Market Commentary: Convertibles quiet; Cemex slips with stock; James River 4.5% adds; Penn Virginia to price
|
10/3/2012 | CV | Market Commentary: New WellPoint up on debut; Ares Capital on tap; existing Ares paper quiet; NuVasive drops
|
10/2/2012 | CV | Market Commentary: WellPoint adds in the gray, models attractively; Molina, Amerigroup quiet; Illumina eyed
|
9/25/2012 | CV | Market Commentary: GT Advanced Technologies lifts despite lower shares; Navistar drops; Amgen, Gilead active
|
9/19/2012 | CV | Market Commentary: New Ctrip.com jumps on debut; Chiquita paper improves; Gilead on a tear; TICC, XPO on tap
|
9/18/2012 | CV | Market Commentary: Suntech adds on production cut; SunPower higher; Alpha Natural up; Hovnanian, Ctrip on tap
|
9/17/2012 | CV | Market Commentary: General Cable up on potential tender; Gilead jumps on HIV drug; AMR holds on to gains
|
9/5/2012 | CV | Market Commentary: Toll Brothers trades unchanged on debut; Medicis in another 0.125 point; IG names active
|
8/31/2012 | CV | Market Commentary: Convertibles mostly flat for week; some see mixed performance for month, but indices gain
|
8/24/2012 | CV | Market Commentary: Convertibles mostly quiet; Gilead comes in slightly; Vertex static; Endo moves up a little
|
8/21/2012 | CV | Market Commentary: MolyCorp trades weakly on second day in the market; Medtronic active ahead of earnings
|
8/20/2012 | CV | Market Commentary: MolyCorp trades weakly on second day in the market; Medtronic active ahead of earnings
|
8/2/2012 | CV | Market Commentary: Knight swings wildly, extends slide after 'glitch'; Gilead adds on rival's suspended trial
|
7/30/2012 | CV | Market Commentary: Convertibles mostly quiet; Kodak gains ahead of auction; Navistar firms; SanDisk mixed
|
7/27/2012 | CV | Market Commentary: Amgen in line to slightly lower on earnings; Gilead, Coinstar in line as well; Amarin off
|
7/24/2012 | CV | Market Commentary: WebMD down on warning; Dendreon better on takeout rumor; Virgin Media tighter after earnings
|
7/19/2012 | CV | Market Commentary: Amgen keeps tracking higher with shares; Xilinx gains on hedge; Kodak retakes 20; AMR up
|
6/27/2012 | CV | Market Commentary: High-grade names in focus; Lennar adds; Isis under pressure; Gevo to price $30 million
|
6/5/2012 | CV | Market Commentary: Central European drops on restatement news; Illumina comes in slightly; Medicines Co. on tap
|
5/31/2012 | SP | Bank of Montreal plans 9% reverse exchangeables on Gilead Sciences
|
4/27/2012 | CV | Market Commentary: Amgen adds 0.25 point on hedge; Micron C notes weaker, but catches bid; Chesapeake pressured
|
4/27/2012 | SP | New Issue: Bank of Montreal prices $555,000 reverse exchangeable notes linked to Gilead Sciences
|
4/19/2012 | CV | Market Commentary: Human Genome adds outright, slides on hedge; New Titan gains dollar neutral; Gilead mixed
|
4/17/2012 | SP | Bank of Montreal plans 11% reverse exchangeables on Gilead Sciences
|
4/13/2012 | CV | Market Commentary: New Microns slip below par in secondary market; Coinstar up on strong preliminary results
|
4/5/2012 | CV | Market Commentary: Convertibles soften ahead of holiday weekend; L-3 steady with lower shares; CETV comes in
|
4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
4/2/2012 | CV | Market Commentary: Convertibles flat to weaker: Gilead weaker, unchanged on hedge; James River down on hedge
|
3/23/2012 | CV | Market Commentary: New Cenveo climbs on debut; Vornado steady, active in trade; investment-grade names mixed
|
3/20/2012 | SP | New Issue: Deutsche Bank prices $940,000 7.5% airbag notes tied to Gilead Sciences
|
3/14/2012 | SP | Deutsche Bank plans 5.85%-7.85% airbag notes linked to Gilead Sciences
|
3/13/2012 | CV | Market Commentary: New Salix pops, then retreats on debut; Medivation talk revised; Wintrust notes to price
|
3/13/2012 | SP | New Issue: UBS prices $2.97 million trigger phoenix autocallables linked to Gilead
|
3/6/2012 | SP | UBS to price trigger phoenix autocallables linked to Gilead Sciences
|
2/29/2012 | SP | New Issue: RBC prices $996,000 11.25% reverse convertibles linked to Gilead Sciences
|
2/22/2012 | CV | Market Commentary: Central European Media slips after disappointing earnings; MGIC adds; NuVasive in focus
|
2/22/2012 | SP | New Issue: UBS prices $166,000 trigger autocallables linked to Gilead Sciences
|
2/22/2012 | SP | New Issue: UBS prices $179,000 trigger autocallables linked to Gilead Sciences
|
2/21/2012 | CV | Market Commentary: Gilead lower outright, mixed on hedge; SunPower, Suntech Power edge up; RadioShack adds
|
2/17/2012 | CV | Market Commentary: Gilead jumps after negative drug study; SunPower gains on earnings beat; Suntech higher
|
2/17/2012 | CVIG | Moody's says Gilead announcement is negative
|
2/16/2012 | SP | RBC to price 11.25% reverse convertibles linked to Gilead Sciences
|
2/14/2012 | CV | Market Commentary: Convertibles weaken some; Gilead mixed; Charles River flat on earnings; DryShips jumps
|
2/10/2012 | CV | Market Commentary: Alcatel-Lucent up on strong earnings; Gilead, Amgen mixed on hedged basis; Siemens prices
|
2/8/2012 | CV | Market Commentary: Gilead edges up further on swap; RadioShack steady; Hutchinson jumps; solar names in focus
|
2/6/2012 | CV | Market Commentary: Convertibles firm; Gilead slips on hedge; DryShips gains outright, little changed on hedge
|
2/3/2012 | CV | Market Commentary: Gilead adds on hedge on positive drug data; Tyson contracts on hedge; MannKind drops deal
|
1/18/2012 | CV | Market Commentary: Amgen, Gilead improve on hedge; D.R. Horton, Synnex trade mostly in line; Cheniere slips
|
1/17/2012 | BK | Gilead enters into three new credit facilities totaling $3 billion
|
12/20/2011 | CV | Market Commentary: Jefferies recoups, moves higher with positive earnings; Navistar looks better on earnings
|
12/19/2011 | CV | Market Commentary: Amgen edges higher; Gilead mixed to higher; Jefferies lower; MF Global adds a few points
|
12/16/2011 | CV | Market Commentary: Gilead lower after trial setback; new AmTrust slips; FiberTower doesn't cure default
|
12/7/2011 | IG | New Issue: Gilead Sciences gives terms of $3.7 billion note sale in four parts
|
12/6/2011 | CVIG | Moody's: Gilead notes Baa1
|
12/6/2011 | IG | New Issue: Gilead Sciences sells $3.7 billion three-, five-, 10-, 30-year notes
|
12/6/2011 | IG | Market Commentary: Gilead, HP, USAA Capital price debt as primary tone holds; HP, Gilead widen ahead of deals
|
12/6/2011 | CV | Market Commentary: Dendreon adds on sale of royalty interest; Gilead trades on debt offering; Clearwire jumps
|
12/6/2011 | CVIG | S&P assigns Gilead notes A-
|
11/29/2011 | CV | Market Commentary: AMR collapses after bankruptcy filing; Transocean Cs improve; Onyx seen lower on hedge
|
11/22/2011 | CV | Market Commentary: Lennar launches new deal; Existing Lennar slips; Frontline tumbles; Gilead bounces some
|
11/21/2011 | CVIG | Moody's affirms Gilead
|
11/21/2011 | BKIG | Gilead Sciences to use loans, notes, cash for Pharmasset acquisition
|
11/21/2011 | CV | Market Commentary: Gilead lower outright, mixed on hedge; Transocean, MF Global lower; 3D Systems prices
|
11/21/2011 | CVIG | S&P affirms Gilead Sciences
|
10/24/2011 | CV | Market Commentary: Convertibles rise on light volume; Radian up; hedged players lose on RightNow's Oracle offer
|
9/12/2011 | CV | Market Commentary: Global Industries surges on takeover offer; Hornbeck up 2-3 points; Clearwire weakens
|
8/17/2011 | CV | Market Commentary: Kodak soars on patent sale speculation; AMD, Intel slip; EMC, Gilead follow market lower
|
6/13/2011 | CVIG | Moody's: Gilead unchanged
|
6/13/2011 | CV | Market Commentary: Convertibles mostly weaker; solar names stabilize, but SunPower lags; BroadSoft to price
|
5/3/2011 | CV | Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
|
4/25/2011 | CV | Market Commentary: Central European Distribution gains outright; RadioShack up after earnings; Apollo on tap
|
4/21/2011 | CV | Market Commentary: Gilead, United Continental slip; Dendreon, WebMD, GM islands of activity in quiet session
|
4/19/2011 | CV | Market Commentary: Gilead, Virgin eyed ahead of earnings; Molina adds on positive results; Clearwire gains
|
4/18/2011 | CV | Market Commentary: Convertibles weaken some; Amylin flat; Gilead mostly lower; A123 Systems sheds a point
|
3/24/2011 | CV | Market Commentary: James River upsizes, jumps on debut; Ares, Gilead add to gains; Best Buy slips with earnings
|
3/23/2011 | CVIGPF | Gilead Sciences files automatic shelf for stock, preferreds and debt
|
3/23/2011 | IG | New Issue: Gilead Sciences sells $1 billion 4.5% 10-year notes at Treasuries plus 125 bps
|
3/23/2011 | IG | Market Commentary: Verizon follows Sanofi with mega-deal, Gilead, Caterpillar price; new bonds firm 1 bp-2 bps
|
3/23/2011 | CV | Market Commentary: Ares, Photronics jump on debuts; Gilead gains on deal; James River up in gray; Kinross up
|
3/23/2011 | CVIG | S&P rates Gilead notes A-
|
3/23/2011 | CVIG | Moody's rates Gilead notes Baa1
|
3/9/2011 | CV | Market Commentary: New WebMD reoffered at 98.75; new TiVo higher but quiet; upsized Cemex, ReneSola on tap
|
1/25/2011 | CV | Citi says replace $15 billion of maturing converts with AngloGold, Boston Properties, among others
|
11/29/2010 | SP | New Issue: RBC prices $1.5 million 11.3% reverse convertibles linked to Gilead Sciences
|
10/20/2010 | CV | Market Commentary: New Cubist trades slightly over par; Amylin gets slammed but pares losses; Gilead quiet
|
8/11/2010 | CV | Gilead greenshoe fully exercised, lifting convertibles to $2.5 billion
|
7/30/2010 | CV | Market Commentary: A&P bonds recoup some losses; Gilead flat; Virgin Media slips; issuance tracks 2009 pace
|
7/28/2010 | CV | Market Commentary: Convertibles crimped by batch of poor earnings; Hutchinson, Kodak, International Game down
|
7/27/2010 | CV | New Issue: Gilead Sciences sells $2.2 billion four-, six-year convertible notes
|
7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
7/26/2010 | CV | Market Commentary: Gilead active, weaker on new notes; AMD mostly quiet, higher on tender; Alcoa trades in line
|
7/26/2010 | CV | New Issue: Gilead Sciences sells $2.2 billion four-, six-year convertible notes
|
7/21/2010 | CV | Market Commentary: Apache up a little in the gray; Genco quiet ahead of pricing; United Rentals, Cephalon add
|
7/20/2010 | CV | Market Commentary: Apache plans $1.1 billion sale of convertible mandatories; MGIC 'comes in' dollar neutral
|
7/19/2010 | CV | Market Commentary: AMR, UAL lower on disappointing Delta earnings; Transocean slips; Newmont Mining steady
|
6/9/2010 | CV | Market Commentary: Microsoft slips below par on debut; Transocean weaker; National Financial, Cadence on tap
|
4/28/2010 | CV | Market Commentary: Convertibles mixed to weaker; PMI, MGIC lower; Newmont Mining up; Synovus at 101 in gray
|
4/23/2010 | CV | Market Commentary: Health care names recover; investment-grade names in focus; Incyte, Textron strengthen
|
4/21/2010 | CV | Market Commentary: MGIC soars on debut; Evergreen Solar active on new issue, tender; Gilead Sciences improves
|
2/1/2010 | SP | New Issue: Bank of America sells $28.6 million 10% reverse mandatory exchangeables on Gilead Sciences
|
1/26/2010 | CV | Market Commentary: Convertibles under pressure; EMC recoups; Amylin strengthens; Kinetic Concepts paper in trade
|
1/25/2010 | CV | Market Commentary: EMC extends losses ahead of earnings; Amgen, Boston Properties little changed; UAL drops
|
10/16/2009 | CV | Market Commentary: Sterlite adds on debut; AMR, Gilead slip lower with shares; AMD stronger after earnings
|
5/12/2009 | CV | Gilead Palo Alto tenders for any and all of $292.22 million 2.75%, 3.25%, 2% convertibles
|
4/27/2009 | CV | Market Commentary: GM rises on exchange; Gilead edges up on swine flu; SunPower, United States Steel to price
|
4/17/2009 | SS | Gilead Sciences completes $20-per-share buyout of CV Therapeutics
|
4/15/2009 | SS | Gilead Sciences to buy 88% of CV Therapeutics' shares in tender offer
|
3/31/2009 | SS | Gilead Sciences, CV Therapeutics merger closer to completion
|
3/18/2009 | SS | CV Therapeutics' board in favor of merger with Gilead Sciences
|
3/16/2009 | SS | Astellas Pharma drops bid for CV Therapeutics
|
3/16/2009 | SS | Market Commentary: Agrium may increase CF Industries bid; CV Therapeutics, Gilead face few regulatory concerns
|
3/13/2009 | SS | Market Commentary: Market unsure of CV Therapeutics bidding war; Roche to close on Genentech before month's end
|
3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
3/12/2009 | SS | CV Therapeutics board rejects Astellas Pharma tender offer
|
3/12/2009 | SS | Gilead agrees to acquire CV Therapeutics for $20 per share
|
3/12/2009 | SS | Market Commentary: Genentech OKs latest bid; bidding war on way for CV Therapeutics; CF Industries pushes for Terra deal
|
3/12/2009 | CV | Gilead to assume $292 million in CV Therapeutics' convertible debt
|
1/21/2009 | CV | Market Commentary: Financial preferreds bounce a little from big drop; health care, biotech names in trade; Avnet edges higher
|
1/21/2009 | SP | RBC to price 13% RevCons linked to Gilead
|
9/2/2008 | CV | Market Commentary: Chesapeake Energy mixed to slightly better as oil falls; Gilead eases; Sciele gains on buyout bid
|
10/19/2007 | CV | Market Commentary: Gilead falls after positive earnings; Medtronic drags down St. Jude; AMD weighs down Intel; Yahoo! gives back
|
3/1/2007 | CV | Market Commentary: Amgen slips on inquiry, drug concerns; Gilead firms on trial results; Hospitality Properties absent in gray
|
12/22/2006 | SP | New Issue: Barclays sells $1 million 8.5% reverse convertibles linked to Gilead
|
12/20/2006 | SP | New Issue: JPMorgan prices $1 million of 8.75% reverse exchangeables linked to Gilead
|
12/6/2006 | SP | Barclays to price 8.5% reverse convertibles linked to Gilead Sciences
|
12/4/2006 | SP | Barclays to price 8.5% reverse convertibles linked to Gilead
|
12/1/2006 | CV | Market Commentary: JDS Uniphase firm on sector concerns; Goodrich quiet in debut; Amgen, Gilead hit on broad pullback
|
10/19/2006 | BT | Gilead at outperform by RBC
|
10/19/2006 | BT | Merrill ups Gilead estimates
|
10/19/2006 | BT | Gilead still at market perform by JMP
|
10/18/2006 | BT | Gilead Sciences ends quarter with $3.2 billion of cash, $52.2 million net loss
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/4/2006 | BT | Gilead rated at outperform by RBC
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
10/3/2006 | BT | Merrill analyst says third-quarter biotech earnings could be mixed
|
10/3/2006 | BT | JMP keeps Gilead at market perform
|
10/2/2006 | BT | Gilead gets neutral rating from Merrill
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
10/2/2006 | CV | Market Commentary: Harrah's offer cuts into hedges; Gilead slips outright on Myogen acquisition; World Acceptance plans deal
|
10/2/2006 | BT | Gilead agrees to acquire Myogen through $2.5 billion transaction
|
9/27/2006 | BT | RBC reiterates Gilead at outperform
|
9/22/2006 | BT | Gilead licenses Viread with eight India-based companies
|
9/22/2006 | BT | Matrix, Gilead to develop generic Tenofovir for HIV/AIDS
|
9/22/2006 | BT | Gilead at outperform by RBC
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/29/2006 | BTCV | New Issue: HSBC USA prices $0.765 million 18% reverse convertibles linked to Gilead Sciences
|
8/14/2006 | BT | Gilead enters agreement to develop Viread in developing countries
|
8/11/2006 | BT | Gilead, Merck to distribute Atripla in developing countries
|
8/11/2006 | BT | RBC picks Gilead, Adolor as biotech underperforms for 2006 to date
|
8/2/2006 | CV | HSBC USA plans issue of reverse convertibles linked to Gilead Sciences
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
7/21/2006 | BT | Gilead maintained at neutral by Merrill
|
7/21/2006 | BT | RBC reiterates Gilead at outperform
|
7/21/2006 | BT | Gilead reiterated at market perform by JMP
|
7/20/2006 | BTCV | Gilead reports second quarter net income of $265.2 million; revenues driven by HIV franchise
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/19/2006 | BT | Gilead to acquire Corus Pharma for $365 million; Novartis to drop Corus lawsuit
|
7/13/2006 | BT | Gilead Sciences to donate $1.1 million annually to establish new research center in Prague
|
7/12/2006 | BT | Bristol-Myers, Gilead get FDA approval for once-daily HIV tablet
|
7/10/2006 | CV | Market Commentary: SanDisk gains on speculation; Gilead improves ahead of results; Archstone-Smith plans overnight deal
|
6/29/2006 | BT | RBC reiterates Gilead outperform rating
|
6/27/2006 | CV | Market Commentary: MedImmune, Gilead trade; Vector launches overnight deal; Chesapeake prices
|
6/20/2006 | CV | Market Commentary: Medtronic, Amgen fall prey to selling pressure; JetBlue adds; Actuant plunges
|
6/15/2006 | BT | Merrill keeps Gilead at neutral
|
6/9/2006 | CV | Market Commentary: Advanced Medical brushes off Fitch downgrade; Gilead, Amgen, Trinity gain; L-3 unchanged
|
6/6/2006 | BT | Gilead Sciences to buy Degussa's Raylo Chemicals for €115.2 million
|
5/26/2006 | CV | Market Commentary: Credence firm despite downgrades; Cubist gains on FDA approval; Nabors, Transocean up with stocks
|
5/18/2006 | BT | RBC quarterly biotechnology update
|
5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
5/11/2006 | BT | Gilead Sciences licenses specialty cancer product DaunoXome to Diatos
|
5/2/2006 | CV | Market Commentary: Apex Silver falls on Bolivia concerns; Quicksilver gains on earnings anticipation; Sirius up on guidance
|
5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
4/27/2006 | BT | Bristol-Myers Squibb, Gilead submit NDA for once-daily single tablet regimen for HIV
|
4/26/2006 | CV | Market Commentary: General Motors' gains boost auto sector; Flextronics up on rival's earnings; Quanta plans $125 million deal
|
4/25/2006 | BTCV | Gilead greenshoe exercised, raising two convertibles to $650 million each
|
4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
4/21/2006 | CV | Market Commentary: Mercury Interactive gains on waiver consent offer; Vitesse marked lower on delayed filings
|
4/20/2006 | CV | Market Commentary: General Motors gains, Intel falls on quarterly results; Gilead new deal stumbles on debut;
|
4/19/2006 | BT | JMP reiterates Gilead at market perform
|
4/19/2006 | CV | Market Commentary: ExpressJet stands firm on lost business; Gilead deal priced cheaper than talk; Cephalon gains on new data
|
4/19/2006 | BTCV | New Issue: Gilead prices $1.2 billion of convertibles; 5-years at 0.5%, up 19%, 7-years at 0.625%, up 17%
|
4/18/2006 | BT | Gilead Sciences says Q1 revenue up 61% on record sales of $559.4 million
|
4/18/2006 | BT | Market Commentary: Gilead pitching jumbo convertible; CV Therapeutics bags $200 million; Labopharm deal emerges; Nabi up
|
4/18/2006 | CV | Market Commentary: Freeport-McMoran surges on strong earnings; JDS Uniphase rebounds; Gilead plans $1.1 billion deal
|
4/18/2006 | BTCV | New Issue: Eksportfinans prices $2.453 million 10% notes linked to Gilead Sciences
|
4/18/2006 | BTCV | Gilead talks $1.1 billion convertibles; 5 years at 0-0.5%, up 20-25%; 7 years at 0.125-0.625%, up 19-24%
|
4/10/2006 | BT | Gilead maintained at neutral by Merrill
|
3/21/2006 | BT | Praecis, Gilead announce option agreement to use DirectSelect technology
|
3/8/2006 | BT | FDA grants traditional approval for Gilead's HIV medications Truvada and Viread
|
2/27/2006 | BT | Market Commentary: Novavax bags $20 million, up 12%; BioCryst, Generex, Gilead also take flight; Cerus deal emerges
|
2/9/2006 | BT | Gilead's GS 9137 decreases viral load during phase 1/2 HIV study
|
2/9/2006 | BT | Gilead kept by Merrill at neutral
|
2/6/2006 | BT | Gilead kept at neutral by Merrill
|
1/31/2006 | BT | Gilead keeps neutral rating from Merrill
|
1/31/2006 | BT | JMP reiterates Gilead at market perform
|
1/10/2006 | BT | Market Commentary: ViroPharma slips; Panacos zooms; Cephalon soars on short covering; Gilead declines; Celgene retraces
|
1/9/2006 | BT | Gilead Science's GS9137 HIV therapy reaches phase 2 trial
|
1/9/2006 | BT | Gilead maintained by Merrill at neutral
|
1/9/2006 | BT | Bristol-Myers Squibb, Gilead collaborate on fixed-dose HIV treatment
|
12/30/2005 | BT | Gilead obtains $300 million term loan, $200 million revolver
|
12/23/2005 | BTCV | New Issue: Morgan Stanley prices $23 million 7.5% Sparqs exchangeable for Gilead Sciences
|
12/12/2005 | BT | Gilead trial of AmBisome for invasive fungal infections provides important dosing information
|
11/30/2005 | BT | 4AZA, Gilead sign agreement to research, develop compounds to treat hepatitis C
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/17/2005 | BT | Market Commentary: Gilead off on reports of deaths; Onyx deal at bat; Durect rises on upgrade, but some buyers hesitate
|
11/17/2005 | BT | Gilead's once-daily HIV drug Truvada more effective than twice-daily Combivir, study shows
|
11/17/2005 | BT | Merrill maintains Gilead Sciences at neutral
|
11/17/2005 | BT | JMP reiterates Gilead at market perform
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
11/16/2005 | BT | Gilead Sciences, Roche end Tamiflu dispute
|
11/8/2005 | BT | William Blair initiates Gilead coverage at market perform
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
10/20/2005 | BT | Market Commentary: Predix IPO put on hold; Amgen spiral continues; Abgenix climbs; generics off despite Tamiflu talks
|
10/19/2005 | BT | JMP maintains Gilead at market perform
|
10/19/2005 | BT | Merrill Lynch maintains Gilead at neutral rating
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
10/17/2005 | BT | Market Commentary: Chiron falls big after closing bell; Biogen, Elan gain; Cephalon up
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
8/10/2005 | BT | Gilead Sciences retained by Merrill at neutral
|
7/20/2005 | BT | Gilead estimates raised by Merrill Lynch
|
7/15/2005 | BT | Genzyme should ultimately outperform Gilead, Merrill report says
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
11/22/2004 | CV | Gilead Sciences says holders converted all $345 million notes ahead of redemption
|
10/6/2004 | CV | Gilead calls all $345 million of 2% convertibles
|
9/30/2004 | CV | Market Commentary: Ford, GM convertibles see little traffic ahead of Sept sales; Schering-Plough shoots up
|
1/30/2004 | CV | Market Commentary: GATX mixed on dividend cut; Nortel results impress players; Gilead weaker on drug worries
|
12/22/2003 | CV | Gilead says all 5% convertibles exchanged for stock ahead of call
|
11/20/2003 | CV | Gilead Sciences to redeem 5% convertibles
|
10/29/2003 | CV | Market Commentary: Gilead plunges 11-30 points on earnings disappointment; Northwest, Elan deals pops up;
|
10/13/2003 | CV | Market Commentary: Beverly Enterprises launches $100 million deal for Wednesday; Ptek pays off on Texas hedge
|
10/2/2003 | CV | Market Commentary: Providian gains sharply amidst big volume on talk about Wells Fargo takeover; buyers aplenty
|
8/28/2003 | CV | Market Commentary: Miscellaneous scraps of convertible paper trading; action to heat up next week
|
8/5/2003 | CV | Market Commentary: Further cheapening noted, but many buyers waiting in wings; new deal slate remains active
|
3/12/2003 | CV | Merrill adds Gilead 2% convertible to model portfolio on attractive risk/reward profile
|
12/16/2002 | CV | Market Commentary: Market watches stocks gain from sidelines, Phoenix in market with small deal
|
12/13/2002 | CV | New Issue: Gilead Sciences $300 million convertibles yield 2.0%, up 25.74%
|
12/13/2002 | CV | Market Commentary: Market treads water while stocks, credit spreads flounder
|
12/12/2002 | CV | Gilead Sciences overnight $300 million convertible talked at 2.0-2.5% yield, up 20-25%
|
12/12/2002 | CV | Market Commentary: Ciena boosts telecom names; market trades sideways amid spate of last-minute new deals
|
9/18/2002 | CV | Market Commentary: JPMorgan tugs on financials, transports fall on war worries
|
8/6/2002 | CV | Market Commentary: Prices, trading volumes gain on short covering, stock bounce
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
5/15/2002 | CV | Market Commentary: Pep Boys advances pricing; market run ends in thud
|
1/4/2002 | CV | Market Commentary: Convertibles higher as prospects of new deals spur activity
|